company background image
REPL

Replimune GroupNasdaqGS:REPL Stock Report

Market Cap

US$1.4b

7D

-15.3%

1Y

-44.0%

Updated

27 Nov, 2021

Data

Company Financials +
REPL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

REPL Stock Overview

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer.

Price History & Performance

Summary of all time highs, changes and price drops for Replimune Group
Historical stock prices
Current Share PriceUS$29.00
52 Week HighUS$54.79
52 Week LowUS$27.66
Beta2.37
1 Month Change-3.17%
3 Month Change-7.82%
1 Year Change-44.05%
3 Year Change93.46%
5 Year Changen/a
Change since IPO91.29%

Recent News & Updates

Oct 01

Replimune: In The 'Buy Zone' Again

Replimune Group, Inc. has lost nearly all its share price gains since mid-October 2020 when it presented encouraging data on two of its oncolytic immunotherapy assets. A news vacuum, a secondary, and a tepid response to an early-June 2021 update to its programs are to blame. With the management team responsible for the only FDA-approved HSV-1 therapy and plenty of catalysts upcoming in 1Q22, Replimune merited a deeper dive. A full investment analysis follows in the paragraphs below.

Sep 02
Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Today we will run through one way of estimating the intrinsic value of Replimune Group, Inc. ( NASDAQ:REPL ) by...

Shareholder Returns

REPLUS BiotechsUS Market
7D-15.3%0.4%-2.7%
1Y-44.0%5.3%21.3%

Return vs Industry: REPL underperformed the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: REPL underperformed the US Market which returned 21.3% over the past year.

Price Volatility

Is REPL's price volatile compared to industry and market?
REPL volatility
REPL Average Weekly Movement5.8%
Biotechs Industry Average Movement8.6%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.3%

Stable Share Price: REPL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: REPL's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015152Philip Astley-Sparkehttps://www.replimune.com

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.

Replimune Group Fundamentals Summary

How do Replimune Group's earnings and revenue compare to its market cap?
REPL fundamental statistics
Market CapUS$1.36b
Earnings (TTM)-US$99.95m
Revenue (TTM)n/a

0.0x

P/S Ratio

-13.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
REPL income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$99.95m
Earnings-US$99.95m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.13
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did REPL perform over the long term?

See historical performance and comparison

Valuation

Is Replimune Group undervalued compared to its fair value and its price relative to the market?

2.97x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: REPL ($29) is trading above our estimate of fair value ($18.59)

Significantly Below Fair Value: REPL is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: REPL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: REPL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate REPL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: REPL's PB Ratio (3x) is in line with the US Biotechs industry average.


Future Growth

How is Replimune Group forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

15.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: REPL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: REPL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: REPL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: REPL's revenue (89.7% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: REPL's revenue (89.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if REPL's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Replimune Group performed over the past 5 years?

-43.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: REPL is currently unprofitable.

Growing Profit Margin: REPL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: REPL is unprofitable, and losses have increased over the past 5 years at a rate of 43.3% per year.

Accelerating Growth: Unable to compare REPL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: REPL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: REPL has a negative Return on Equity (-21.85%), as it is currently unprofitable.


Financial Health

How is Replimune Group's financial position?


Financial Position Analysis

Short Term Liabilities: REPL's short term assets ($444.4M) exceed its short term liabilities ($16.6M).

Long Term Liabilities: REPL's short term assets ($444.4M) exceed its long term liabilities ($29.4M).


Debt to Equity History and Analysis

Debt Level: REPL is debt free.

Reducing Debt: REPL had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: REPL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if REPL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Replimune Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate REPL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate REPL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if REPL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if REPL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of REPL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Philip Astley-Sparke (50 yo)

1.83yrs

Tenure

US$2,457,592

Compensation

Mr. Philip Astley-Sparke, FSA, had been the Independent Non-Executive Chairman of uniQure N.V. since September 22, 2016 until June 17, 2021 and its Independent Non-Executive Director since June 15, 2015 un...


CEO Compensation Analysis

Compensation vs Market: Philip's total compensation ($USD2.46M) is below average for companies of similar size in the US market ($USD3.64M).

Compensation vs Earnings: Philip's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: REPL's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: REPL's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2%.


Top Shareholders

Company Information

Replimune Group, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Replimune Group, Inc.
  • Ticker: REPL
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.360b
  • Shares outstanding: 46.89m
  • Website: https://www.replimune.com

Number of Employees


Location

  • Replimune Group, Inc.
  • 500 Unicorn Park Drive
  • 3rd Floor
  • Woburn
  • Massachusetts
  • 1801
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/27 23:23
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.